The vital role CS plays in eliciting protective immunity as a stand-alone vaccine [63], in combination with additional sporozoite antigens [64], or in a heterologous prime-and-trap vaccination regimen with whole-organism sporozoites [57,65,66], validates the CS protein as a viable target antigen for malaria vaccine development. The gene discussed is CS; the disease is malaria.